Arch Biopartners wins central IRB approval for U.S. Phase II CS-AKI trial expansion
AI Summary- Arch Biopartners received central IRB approval for its Phase II LSALT peptide trial.
- The trial targets 240 patients with cardiac surgery-associated acute kidney injury.
- U.S. sites are expected to need four to six months before first-patient dosing.